Foghorn Therapeutics Inc. (FHTX) stock
Close on Nov 11, 2026Market cap $124.12MP/E 29.9Yield –
Foghorn Therapeutics Inc. grew revenue 357.3% to $112.13M over the twelve months to Sep 30, 2026. Free cash flow was -$83.68M. At the latest close the market valued the company at $124.12M, 29.9 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $124.12M
- P/E ratio
- 29.9
- Price to sales
- 1.11
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -67.42%
Fundamentals
- Revenue
- $112.13M
- Net income
- $9.42M
- EPS, diluted
- $0.07
- Free cash flow
- -$83.68M
- Book value per share
- -$0.19
- Diluted shares
- 73M
Trading
- Next earnings
- Mar 10, 2027 (estimated, after the close)
- Previous close
- $1.90
- Open
- $1.95
- Day's range
- $1.88 – $2.10
- Volume
- 761,431
- Average volume (20 days)
- 681,050
- Index membership
- Russell 2000 (since Dec 2020)
- Beta (5 years)
- 1.87
- 52-week range
- $1.79 – $7.61
- RSI (14 days)
- 42.1
- Volatility (1 year)
- 81.4%
- Relative volume
- 1.16×
- WACC
- 14.2%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | FHTX | S&P 500 | Difference | FHTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +4.5% | -2.4% | +6.9 pts | ||
| 3 months | -68.3% | -1.2% | −67.1 pts | ||
| Year to date | -61.3% | +12.3% | −73.6 pts | ||
| 1 year | -52.9% | +12.4% | −65.4 pts | ||
| 3 years | -35.3% | +78.8% | −114.1 pts | -13.5% | +21.4% |
| 5 years | -84.9% | +75.2% | −160.1 pts | -31.5% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Foghorn Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Results
About Foghorn Therapeutics
Pharmaceutical Preparations
Foghorn is a clinical-stage biotechnology enterprise that develops precision therapeutics designed to treat serious diseases, primarily cancers. The company targets the chromatin regulatory system to correct aberrant gene expression orchestrating disease progression. Leveraging its proprietary Gene Traffic Control platform, Foghorn identifies genetically determined dependencies within diseased cells to discover and design small molecule drug candidates, such as enzymatic inhibitors, targeted protein degraders, and transcription factor disruptors. Its lead candidate, FHD-909, is an orally administered selective SMARCA2 inhibitor undergoing Phase 1 clinical testing for non-small cell lung cancer and solid tumors in collaboration with Eli Lilly and Company.
Company profile, executives and historyFoghorn Therapeutics stock: common questions
What is Foghorn Therapeutics's stock price?
FHTX closed at $2.09 on Nov 11, 2026, up 10.00% on the day. Over the past 52 weeks it traded between $1.79 and $7.61.
What is Foghorn Therapeutics's market cap?
Foghorn Therapeutics was worth $124.12M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is FHTX's P/E ratio?
FHTX trades at 29.9 times earnings, based on diluted earnings per share of $0.07 over the twelve months to Sep 30, 2026.
How much revenue does Foghorn Therapeutics make?
Foghorn Therapeutics reported revenue of $112.13M for the twelve months to Sep 30, 2026, up 357.3% from a year earlier.
Does Foghorn Therapeutics pay a dividend?
No. Foghorn Therapeutics has not paid a cash dividend over the last twelve months.
When does Foghorn Therapeutics report earnings next?
Foghorn Therapeutics is expected to report Q4 FY2026 results on Mar 10, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has FHTX stock performed over the past year?
Including dividends, FHTX returned -52.9% over the past year, against +12.4% for the S&P 500.
How many FHTX shares are sold short?
2M shares were sold short at the latest FINRA report, 5.95% of the float, or 3.9 days of average trading volume.
Who are Foghorn Therapeutics's competitors?
Companies most similar to Foghorn Therapeutics by business, industry and size include TNGX, FULC, RCUS, PGEN, BCYC.
See a number that looks wrong?